Franklin Resources Inc. lessened its holdings in Vascular Biogenics Ltd. (NASDAQ:VBLT) by 50.2% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 452,677 shares of the biopharmaceutical company’s stock after selling 456,414 shares during the period. Franklin Resources Inc. owned approximately 1.68% of Vascular Biogenics worth $2,014,000 at the end of the most recent reporting period.

Separately, Menta Capital LLC boosted its stake in shares of Vascular Biogenics by 5.4% in the 1st quarter. Menta Capital LLC now owns 121,935 shares of the biopharmaceutical company’s stock worth $671,000 after buying an additional 6,200 shares during the last quarter. Institutional investors own 11.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/01/vascular-biogenics-ltd-vblt-shares-sold-by-franklin-resources-inc.html.

Vascular Biogenics Ltd. (VBLT) opened at 6.10 on Friday. The company has a 50-day moving average price of $4.93 and a 200 day moving average price of $5.16. The stock’s market cap is $164.75 million. Vascular Biogenics Ltd. has a 1-year low of $3.90 and a 1-year high of $7.25.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Equities analysts expect that Vascular Biogenics Ltd. will post ($0.74) earnings per share for the current fiscal year.

A number of brokerages have recently weighed in on VBLT. ValuEngine downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Wednesday. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Finally, HC Wainwright set a $11.00 target price on Vascular Biogenics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. Vascular Biogenics presently has a consensus rating of “Hold” and an average target price of $12.90.

Vascular Biogenics Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Want to see what other hedge funds are holding VBLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vascular Biogenics Ltd. (NASDAQ:VBLT).

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.